References (in alphabetical order)
Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984; 10: 24-41.
Arkin S, Cooper HA, Hutter JJ, Miller S, Schmidt ML, Seibel NL, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the Recombinant Factor VIIa emergency-use program. Hemostasis 1998; 28: 93-98.
Astrup T. Tissue activators of plasminogen. Fed Proc 1966; 25: 42-51.
Bajaj MS, Rana SV, Wysolmerski RB, et al. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878.
Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-1937.
Blombäck B, Blombäck M. The molecular structure of fibrinogen. Ann NY Acad Sci 1972; 202: 77-97.
Bregengaard C, Diness V, Hedner U. Effect of recombinant factor VIIa on endotoxin-induced disseminated intravascular coagulation in rabbits. Thromb Hemost 1993; 69: 749.
Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA 1989; 86: 1382-1386.
Budzinski AZ, Olexa SA, Pandya BV. Fibrin ploymerization sites in fibrinogen and fibrin fragments. Ann NY Acad Sci 1983; 408: 301-313.
Castellino FJ. Biochemistry of human plasminogen. Semin Thromb Hemost 1984;10: 18-23.
Chesney CM, Piffer D, Colman RW. Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci 1981; 78: 5181-5184.
Cines DB, Polack ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of avascular disorders. Blood 1998; 91: 3627-3261.
Cohen I, Blankenberg TA, Borden D, et al. Factor XIIIa catalysed cross-linking of platelet and muscle actin. Regulation by nucleotides. Biochim Biophys Acta 1980; 628: 365-375.
Conlan MG, Hoots WK. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol 1990; 35: 203-207.
Davey RJ, Shashaty GG, Rath CE. Acute coagulopathy following infusion of prothrombin complex concentrate. Am J Med 1976; 60: 719-722.
Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312.
Dieval J, Nguyen G, Gross S, et al. A life-long bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-532.
Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530.
Esmon CT. Regulation of blood coagulation. Biochemica et Biophysica Acta 2000; 1477: 349-360.
Folk JE, Finlayson JS. The Î (g-glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 1977; 31: 1-133.
Forbes CD, Thomas SP, et al (eds). Haemostasis and Thrombosis, 1994; 3rd ed. Edinburgh, Churchill Livingstone 59-285.
Friederich PW, Levi M, Bauer K, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR. Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects. Circulation 2001; 103: 2555-2559.
Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.
Girard P, Nony P, Erhardtsen E, Delair S, Ffrench P, Dechavanne M et al. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Hemost 1998; 80: 109-113.
Green D. Complications associated with the treatment of hemophiliacs with inhibitors. Hemophilia 1999; 5 (suppl 3): 11-17.
Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicentre study. Thromb Hemost 1997; 78: 1463-1467.
Hoffman M, Monroe III DM. The action of high dose factor VIIa (FVIIa) in a cell-based model of hemostasis. In: Treatment of Bleeding and Thrombotic Disorders. Semin Hematology (suppl) 2001;in press.
Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, et al. Major surgery in hemophilic patients with inhibitors using recombinant factor VIIa. Hemostasis 1996; 26 (suppl 1): 118-123.
Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor VII deficient patients. Hemophilia 1997; 3: 215-218.
Kaplan KL, Broekman MJ, Chernoff A, et al. Platelet a-granule proteins: Studies on release and subcellular localization. Blood 1979; 53: 604-618.
Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Recombinant Factor VIIa) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912-918.
Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Recombinant Factor VIIa) in hemophiliacs with inhibitors. Thromb Hemost 1998; 80: 912-918.
Kim HC, McMillan CW, White GC, et al. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in haemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-575.
Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50-68.
Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost. 2001;86:757-71.
Kowalski E. Fibrinogen derivatives and their biological activities. Semin Hematol 1968; 5: 45-59.
Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; (suppl 1) 26: 159-164.
Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL. Activated recombinant human coagulation factor VII (recombinant Factor VIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63: 109-113.
Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
Loskutoff DJ, Sawdey M, Keeton M, et al. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993; 70: 135-137.
Lund-Hansen T, Petersen LC. Comparison of enzymatic properties of human plasma FVIIa and human recombinant FVIIa. Thromb Hemost 1987; 58: 270. Note for Guidance on Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95 1995. Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses. CPMP/BWP/268/95 1995; 75/318/EEC.
Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors. recombinant Factor VIIa Study Group. Hemophilia 1998; 4: 790-798.
Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in haemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial. N Engl J Med 1980; 303: 421-425.
Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J HematoL Suppl 1998; 61: 7-10.
MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 1964; 202: 498-499.
McPherson J, Teague L, Lloyd J, Jupe D, Rowell J, Ockelford P, et al. Experience with recombinant factor VIIa in Australia and New Zealand. Hemostasis 1996; 26 Suppl 1: 109-117.
Meijer K, Peters FTM, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coag Fibrin 2001;12: 211-213.
Moisescu E, Ardelean I, Simion I, Muresen A, Ciupan R. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis 2000; 11: 575-577.
Monroe DM, Hoffman M, Allen G, Roberts H. The factor VII-platelet interplay: Effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Sem Throm Hemost 2000; 26: 373-377.
Nemerson Y, Esnouf MP. Activation of a proteolytic system by a membrane lipoprotein: mechanism of action of tissue factor. Proc Natl Acad Sci USA 1973; 70: 310-314.
Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992; 29: 170-176.
Ohga S, Saito M, Matzukazi A, et al. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy. Br J Haematol 1993; 84: 343-345.
Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa [letter]. Thromb Haemost 1998; 80: 352.
Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94: 3951-3953.
Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
Repke D, Gemmell CH, Guha A, Turitto VT, Broze GJJ, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990; 87: 7623-7627.
Revesz T, Arets B, Bierings M, van den Bos C, Duval E. Recombinant factorVIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 353.
Roberts H, Monroe DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of haemostasis. In: Beutler E et al,(eds). Williams Haematology. New York: Mc-Graw-Hill Medical PublishingDivision, 2001: 1409-1434.
Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; (suppl 1) 9: S115-S118.
Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9 (suppl 1): S115-S118.
Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984; 74: 1-6.
Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7: 308-316.
Sakai T, Lund-Hansen T, Thim L, Kisiel W. The gamma-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor. J Biol Chem 1990; 265: 1890-1894.
Sakata Y, Aoki N. Cross-linking of a2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-297.
Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervation. Br J Hematol 1999; 104: 22-26.
Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Hemophilia 1999; 5: 253-259.
Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of recombinant Factor VIIa (Recombinant Factor VIIa) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of recombinant Factor VIIa (Recombinant Factor VIIa) in hemophilia patients with inhibitors undergoing surgery. Thromb Hemost 1998; 80: 773-778.
Sie P, Dupouy D, Pichon J, et al. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet 1985; 2: 414-416.
Sixma JJ. Interaction of blood platelets with the vessel wall. In Bloom AL,
Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII: A double-blind clinical trial. N Engl J Med 1981; 305: 717-721.
Small M, Lowe GDO, Douglas JT, et al. Factor IX thrombogenicity: In vivo effects on coagulation activation and a case report of disseminated intravascular coagulation. Thromb Haemost 1982; 48: 76-77.
Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-168.
Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa [letter]. Thromb Haemost 1996; 75: 981-982.
Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-7793.
Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II: Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169.
Varon D, Martinowitz U, Heim M (Guest editors). State of the art. Inhibitors of coagulation factors. Hemophilia 1998; 4: 538-628.
White JG, Gerrard JM. Ultrastructural features of abnormal platelets. A review. Am J Pathol 1976; 83: 589-632.
Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80:25-28.
Zucker MB, Broekman MJ, Kaplan KL. Factor VIII-related antigen in human blood platelets. J Lab Clin Med 1979; 94: 675-682.
Prescribing Info - Questions - Drug Info - Links - PDA Software - Article Summaries - Slideshows - Review Articles - What's New
© Copyright 1999-2020 All Rights Reserved.